- 8017 Labana Ct, Canton Township, MI 48187
- +1 (734) 418 2537
- info@a2zbillings.com
Before a claim goes out, we confirm whether the biologic your patient needs is billed as a medical claim or dispensed through a specialty pharmacy. Get that wrong and the visit, the drug, or both can go unpaid.
A rheumatology claim can be billed correctly and still get denied.
Rheumatology patients rarely carry one diagnosis. A single visit note might track rheumatoid arthritis, osteoporosis from years of prednisone, and a lab panel monitoring a DMARD, all in the same encounter. Each of those threads has its own billing rule, and none of them wait for the others to get sorted out first.
The bigger complication sits upstream of coding. Before a biologic is ever administered, someone has to confirm whether that specific drug, for that specific patient's plan, is paid under the medical benefit through buy-and-bill or routed through a specialty pharmacy under the pharmacy benefit. Bill a drug the payer already paid a pharmacy for, and the claim comes back as a full denial, not a partial one.
A2Z Billings works with rheumatology practices and infusion clinics across the country on this exact layering of decisions, from benefit verification through the last denied line.
Many biologics used in rheumatology can be billed either as a medical claim after the practice purchases and administers the drug, or through a specialty pharmacy under the pharmacy benefit. The same medication can be covered under either channel depending on how the patient's plan is built, and mixing them up is one of the fastest ways to lose an entire claim.
Under buy-and-bill, the practice purchases the biologic from a wholesaler or distributor, administers it in the office, and bills the payer for both the drug and the administration under the medical benefit. This is the standard path for most infused biologics and for many of the injectable drugs rheumatologists keep in stock.
Some of the same drugs, and a growing number of self-injectable biologics, move through the pharmacy benefit instead. A specialty pharmacy dispenses the medication, sometimes shipping it directly to the practice for the patient to receive there, a pattern often called white bagging. The claim for the drug itself runs through the pharmacy benefit manager, not the medical claim the practice submits.
When the channel gets confused, the results are not small. A practice that bills a J-code for a drug the payer already paid a specialty pharmacy for will see that claim denied outright, and a practice that assumes a drug sits on the pharmacy benefit when the plan actually requires buy-and-bill can delay a patient's treatment while the paperwork gets sorted out. Confirming the channel before the drug is ordered is not an administrative afterthought. It decides whether the claim can be paid at all.
Four categories account for most of the coding decisions on a rheumatology claim, and most of the denials trace back to one of them.
Chronic care coordination. Many rheumatology patients qualify for chronic care management because they carry two or more conditions expected to last a year or longer, a description that fits rheumatoid arthritis alongside osteoporosis or a second autoimmune diagnosis without much effort. Non-complex CCM is billed in twenty-minute increments of clinical staff time directed by the physician, and separately, in thirty-minute increments, when the physician personally provides the care coordination. Practices that already do this coordination work by phone and portal message are often just not billing for it.
Bone health crossover. Long-term corticosteroid use is common in rheumatology, and it raises fracture risk enough that bone density monitoring often needs to happen sooner than the routine interval most payers default to, which is typically once every two years. A scan of the spine and hips uses one code, a peripheral site like the wrist or heel uses another, and billing either one without a diagnosis or documented risk factor that justifies the earlier timing is a common way to lose the claim.
Same-day joint procedures. A patient with polyarticular disease may need injections in more than one joint at a single visit. The rule is one billed unit per joint, with a bilateral modifier for paired joints like both knees, and a distinct-procedure modifier when the joints are not symmetrical, such as a shoulder and the opposite knee. Billing multiple joints under a single line, or leaving the modifier off, tends to collapse the claim down to one payment.
Drug identification. Every buy-and-bill drug line needs to identify not just the general HCPCS code, but the specific product administered. A growing number of Medicaid programs, along with a number of commercial payers, require the National Drug Code on the same claim line as the HCPCS code, and the two have to correspond to the same product. Missing or mismatched NDCs are one of the more mechanical, and more preventable, reasons a drug line gets rejected outright.
These four patterns account for a disproportionate share of the denials we see on rheumatology claims, and every one of them is preventable with the right check in place.
When a biologic is routed through the pharmacy benefit, either through a specialty pharmacy or a white-bagging arrangement, billing the practice’s own J-code for that same drug on the medical claim results in an outright denial, since the payer has already reimbursed the pharmacy for it.
Fix Confirm the benefit channel for each biologic before it’s ordered, not after the claim is filed.
A growing list of Medicaid programs and commercial payers reject a drug claim line when the National Drug Code is missing, or when it doesn’t correspond to the HCPCS code billed alongside it.
Fix Confirm the NDC against the vial actually administered, not a default saved in the system.
Injecting two different, non-paired joints at the same visit and billing them as a single line, or leaving off the modifier that identifies the second joint as a distinct procedure, causes the payer to collapse the claim to one payment.
Fix Bill one unit per joint and append the bilateral or distinct-procedure modifier that matches the anatomy.
Most payers cover a bone density study on a set interval, and billing a repeat scan sooner without documenting the reason, such as long-term steroid use, an existing fracture, or a change in treatment, gets the claim treated as not medically necessary.
Fix Tie any early repeat DXA to the specific documented risk factor that justifies it.
The same note often has to support a visit, a procedure, and a drug decision, so it needs to carry more than a summary of symptoms.
A lot of rheumatology revenue is decided before the first claim is ever filed.
Because so much of rheumatology billing depends on a decision made before the visit even happens, our process starts earlier than most billing relationships do.
Before a biologic is scheduled, we verify whether that specific drug, for that specific plan, is billed under the medical benefit or routed through a specialty pharmacy.
Benefits, authorization status, and any frequency exception, such as an early DXA or added chronic care time, are confirmed before the visit takes place.
The E/M, any joint injections, drug administration, and chronic care time from the same visit are coded together, with modifiers, units, and NDC checked against the documentation.
When a channel-mismatch, NDC, or modifier denial arrives, we correct and refile it rather than writing it off, then reconcile it at payment posting.
It depends on the specific drug and the specific patient’s plan, not on the diagnosis. The same biologic can be covered either way depending on how the payer has built that plan’s benefit design. We check this before the drug is ordered, since billing the wrong channel usually means a full denial rather than a partial one.
The HCPCS code identifies a category of drug, not always the specific manufacturer or package it came from. A growing number of Medicaid programs and commercial payers require the NDC alongside the HCPCS code to confirm exactly what was administered, and the two have to correspond to the same product.
Yes, with the right modifier. Bill one unit per joint treated. Paired joints, like both knees, are reported as one line with a bilateral modifier. Different, non-symmetrical joints, like a shoulder and the opposite knee, are billed as separate lines with a distinct-procedure modifier on the second one.
Yes. A patient managing rheumatoid arthritis alongside osteoporosis or a second chronic condition often already qualifies, and the coordination work many practices already do by phone or portal message can be billed if the time is logged correctly. We help set up that tracking and code it monthly.
Most payers default to covering a routine scan once every two years, but long-term corticosteroid use is a recognized reason to scan sooner. The claim needs to document the steroid dose and duration, or another qualifying risk factor, to support billing outside the routine interval.
It happens more often than practices expect, usually at a plan renewal. When it does, continuing to bill the drug on the medical claim results in denials even though nothing about the patient’s treatment changed. We watch for these channel shifts at reauthorization so the billing catches up before claims start bouncing.
